The Phase 1b MUIR data shows azenosertib + paclitaxel meaningfully improves ORR and PFS vs. historical paclitaxel monotherapy benchmarks in heavily pre-treated PROC. The 250 mg intermittent dose suggests manageable safety. With the company's core registration strategy in Cyclin E1-positive monotherapy, this combination proof-of-concept expands the total addressable market. Expect stock volatility around the ASCO presentation on June 1, but given the early-phase nature and small sample sizes, the filing alone is a moderate positive catalyst, not a transformational event.
ZNTL drugs
ZNTL drug pipeline →How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · May 22 $4.06entry
- T+1 · 6mo ago −2.46%α −3.05% · $3.96
- T+5 · 6mo ago −1.97%α −3.63% · $3.98
- T+20 · 5mo ago −8.87%α −7.45% · $3.70
- T+60 · 3mo ago −9.36%α −12.55% · $3.68
Price Chart
How similar events traded
Executive Summary
Zentalis Pharmaceuticals announced Phase 1b MUIR trial data for azenosertib plus paclitaxel in platinum-resistant ovarian cancer (PROC), showing a 39.1% ORR and 7.3-month median PFS across all cohorts (n=46), with a 50% ORR and 9.2-month median DOR at the 250 mg intermittent dose (n=12). The data will be presented at ASCO 2026. As a pre-revenue biotech with a $264M market cap, the filing is noteworthy for pipeline progress but does not change the risk profile.
Key Facts
- ORR of 39.1% across all four dose cohorts (n=46) in PROC patients, vs. historical paclitaxel monotherapy ORR of ~30%.
- At the 250 mg intermittent dose (n=12), ORR was 50.0% including one complete response, with a median DOR of 9.2 months.
- Median PFS of 7.3 months across all cohorts vs. historical paclitaxel monotherapy median PFS of ~4 months.
- One Grade 5 event (sepsis) previously reported in June 2024, assessed as related to azenosertib by investigator.
- Data will be presented at ASCO 2026 (June 1, 2026).
Financial Impact
No financial data in filing; clinical data supports potential expansion of azenosertib label into combination settings, which could increase peak revenue opportunity if approved.
Risk Factors
- Small Phase 1b sample (n=46), data may not replicate in larger randomized trials.
- Grade 5 event (sepsis) attributed to azenosertib remains a safety concern.
- No financial data filed, company has significant cash burn with no approved products.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001725160-26-000045 |
| Document: asco2026datapressreleasefi.htm | 0001725160-26-000045 |
| Document: 0001725160-26-000045-index-headers.html | 0001725160-26-000045 |
| Document: 0001725160-26-000045-index.html | 0001725160-26-000045 |
| Document: 0001725160-26-000045.txt | 0001725160-26-000045 |
Track record
18 reports on ZNTL
5 of 7 bullish or bearish reports moved the stock their way by T+60. Best: +51.42% at T+60 after the Aug 14, 2026 report. 6 of 9 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 4/10 Entry $1.62 Now $1.60 −1.23% settles Feb 12
- Nov 9, 20267d ago 8-K Bearish 5/10 Entry $1.80 Now $1.60 +11.11% settles Feb 8
- Oct 27, 202620d ago SC 13G/A Neutral 3/10 Entry $2.06 Now $1.60 −22.33% settles Jan 26
- Oct 18, 202629d ago Press Release Bullish 7/10 Entry $2.30 Now $1.60 −30.43% settles Jan 14
- Oct 1, 20266w ago Press Release Neutral 2/10 Entry $2.52 Now $1.60 −36.51% settles Dec 29
- Aug 14, 202613w ago 8-K Bearish 6/10 Entry $3.71 to $1.80 Now $1.60 +56.82% ▲ +51.42% +48.47% vs SPY
- Aug 13, 202613w ago Press Release Bearish 6/10 Entry $3.56 to $1.74 Now $1.60 +55.06% ▲ +51.12% +48.08% vs SPY
- Jun 11, 202622w ago Institutional Cluster Mixed 4/10 Entry $3.75 to $4.03 Now $1.60 −57.33% ▲ +7.47% +4.20% vs SPY
- Jun 1, 202624w ago Press Release Neutral 2/10 Entry $3.95 to $3.89 Now $1.60 −59.49% ▼ −1.52% −2.64% vs SPY
- May 21, 202625w ago Press Release Bullish 6/10 Entry $4.06 to $3.68 Now $1.60 −60.59% ▼ −9.36% −12.55% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers